Dialysepatienten

Zusammenfassung

Blutdruckprobleme sind beim Dialysepatienten ein alltägliches Problem. Während wir mittlerweile sehr gut wissen, welche Ziele wir in der Blutdrucktherapie beim nierengesunden Patienten anstreben, so sind die entsprechenden Zielwerte für Dialysepatienten deutlich weniger klar. Durch das terminale Versagen der Niere erscheint der kardiovaskuläre Risikofaktor Hypertonie entschärft zu werden, da andere, urämiebedingte Risikofaktoren für die kardiovaskuläre Mortalität dominanter werden. Darüber hinaus ändert sich die Blutdruckregulation bei Dialysepatienten erheblich. In der vorliegenden Übersicht wird zusammengefasst, wann und wie bei Dialysepatienten der Blutdruck gemessen werden sollte. Außerdem werden neben den möglicherweise zu erreichenden Blutdruckzielen auch die derzeit bekannten Behandlungsstudien zusammenfassend dargestellt.

• Literatur

• 1 K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 (Suppl. 03) S1-S153
• 2 Tentori F, Hunt WC, Rohrscheib M. et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?. J Am Soc Nephrol 2007; 18: 2377-2384 doi:10.1681/ASN.2006111250
• 3 Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008; 73: 759-764 doi:10.1038/sj.ki.5002745
• 4 Mark PB, Johnston N, Groenning BA. et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-1845 doi:10.1038/sj.ki.5000249
• 5 Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ Arrhythm Electrophysiol 2010; 3: 553-559 doi:10.1161/CIRCEP.110.937888
• 6 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (Suppl.) S16-S23
• 7 Wanner C, Krane V, März W. et al. ; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 doi:10.1056/NEJMoa043545
• 8 Fellström BC, Jardine AG, Schmieder RE. et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407 doi:10.1056/NEJMoa0810177
• 9 Jardine AG. Con: Ambulatory blood pressure measurement in patients receiving haemodialysis: a sore arm and a waste of time?. Nephrol Dial Transplant 2015; 30: 1438-1441 doi:10.1093/ndt/gfv244
• 10 Sigrist MK, McIntyre CW. Vascular calcification is associated with impaired microcirculatory function in chronic haemodialysis patients. Nephron Clin Pract 2008; 108: c121-c126 doi:10.1159/000114202
• 11 Shoji T, Tsubakihara Y, Fujii M. et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66: 1212-1220 doi:10.1111/j.1523–1755.2004.00812.x
• 12 Burton JO, Jefferies HJ, Selby NM. et al. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4: 914-920 doi:10.2215/CJN.03900808
• 13 McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. Semin Dial 2010; 23: 449-451 doi:10.1111/j.1525–139X.2010.00782.x
• 14 Eldehni MT, McIntyre CW. Are there neurological consequences of recurrent intradialytic hypotension?. Semin Dial 2012; 25: 253-256
• 15 Assa S, Hummel YM, Voors AA. et al. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 2012; 7: 1615-1623 doi:10.2215/CJN.00850112
• 16 Agarwal R. Pro: Ambulatory blood pressure should be used in all patients on hemodialysis. Nephrol Dial Transplant 2015; 30: 1432-1437 doi:10.1093/ndt/gfv243
• 17 Li Z, Lacson E, Lowrie EG. et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: 606-615 doi:10.1053/j.ajkd.2006.07.005
• 18 Klassen PS, Lowrie EG, Reddan DN. et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548-1555
• 19 Port FK, Hulbert-Shearon TE, Wolfe RA. et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney 1999; 33: 507-517
• 20 Bansal N, McCulloch CE, Rahman M. et al. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension 2015; 65: 93-100 doi:10.1161/HYPERTENSIONAHA.114.04334
• 21 Foley RN, Herzog CA, Collins AJ. United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790 doi:10.1046/j.1523–1755.2002.00636.x
• 22 FHN Trial Group. Chertow GM, Levin NW, Beck GJ. et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300 doi:10.1056/NEJMoa1001593
• 23 Chertow GM, Levin NW, Beck GJ. et al. Frequent Hemodialysis Network (FHN) Trials Group. Long-Term Effects of Frequent In-Center Hemodialysis. J Am Soc Neph 2016; 27: 1830-1836 doi:10.1681/ASN.2015040426
• 24 Stidley CA, Hunt WC, Tentori F. et al. Medical Directors of Dialysis Clinic Inc.. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006; 17: 513-520 doi:10.1681/ASN.2004110921
• 25 Chazot C, Vo-Van C, Deleaval P. et al. Predialysis systolic blood pressure evolution in incident hemodialysis patients: effects of the dry weight method and prognostic value. Blood Purif 2012; 33: 275-283 doi:10.1159/000337101
• 26 Piper MA, Evans CV, Burda BU. et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 162: 192-204 doi:10.7326/M14–1539
• 27 Agarwal R, Sinha AD, Light RP. Toward a definition of masked hypertension and white-coat hypertension among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2003-2008 doi:10.2215/CJN.02700311
• 28 Ben-Dov IZ, Kark JD, Ben-Ishay D. et al. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension 2007; 49: 1235-1241 doi:10.1161/HYPERTENSIONAHA.107.087262
• 29 Amar J, Vernier I, Rossignol E. et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000; 57: 2485-2491 doi:10.1046/j.1523–1755.2000.00107.x
• 30 Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2: 1228-1234 doi:10.2215/CJN.02250507
• 31 Agarwal R, Andersen MJ, Light RP. Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008; 28: 210-217 doi:10.1159/000110090
• 32 Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53: 860-866 doi:10.1161/HYPERTENSIONAHA.108.128116
• 33 Heerspink HJ, Ninomiya T, Zoungas S. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015 doi:10.1016/S0140–6736(09)60212–9
• 34 Iseki K, Arima H, Kohagura K. et al. Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28: 1579-1589 doi:10.1093/ndt/gfs590
• 35 Nishimura M, Tokoro T, Nishida M. et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. Am J Kidney Dis 2009; 54: 303-317 doi:10.1053/j.ajkd.2009.03.025
• 36 Cice G, Di Benedetto A, D’Isa S. et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-1708 doi:10.1016/j.jacc.2010.03.105
• 37 Matsumoto Y, Mori Y, Kageyama S. et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63: 528-536 doi:10.1016/j.jacc.2013.09.056
• 38 Agarwal R, Sinha AD, Pappas MK. et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014; 29: 672-681 doi:10.1016/j.jacc.2013.09.056